OVID vs. IMUX, BDSI, SAGE, GYRE, CVAC, IRON, TYRA, ABVX, ZNTL, and CNTA
Should you be buying Ovid Therapeutics stock or one of its competitors? The main competitors of Ovid Therapeutics include Immunic (IMUX), BioDelivery Sciences International (BDSI), Sage Therapeutics (SAGE), Gyre Therapeutics (GYRE), CureVac (CVAC), Disc Medicine (IRON), Tyra Biosciences (TYRA), ABIVAX Société Anonyme (ABVX), Zentalis Pharmaceuticals (ZNTL), and Centessa Pharmaceuticals (CNTA). These companies are all part of the "medical" sector.
Immunic (NASDAQ:IMUX) and Ovid Therapeutics (NASDAQ:OVID) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, risk, profitability, analyst recommendations, valuation, earnings, dividends and community ranking.
Ovid Therapeutics has higher revenue and earnings than Immunic. Ovid Therapeutics is trading at a lower price-to-earnings ratio than Immunic, indicating that it is currently the more affordable of the two stocks.
Immunic has a net margin of 0.00% compared to Immunic's net margin of -10,691.14%. Immunic's return on equity of -53.62% beat Ovid Therapeutics' return on equity.
Ovid Therapeutics received 251 more outperform votes than Immunic when rated by MarketBeat users. Likewise, 70.55% of users gave Ovid Therapeutics an outperform vote while only 65.73% of users gave Immunic an outperform vote.
Immunic has a beta of 1.93, meaning that its stock price is 93% more volatile than the S&P 500. Comparatively, Ovid Therapeutics has a beta of 0.69, meaning that its stock price is 31% less volatile than the S&P 500.
In the previous week, Ovid Therapeutics had 1 more articles in the media than Immunic. MarketBeat recorded 3 mentions for Ovid Therapeutics and 2 mentions for Immunic. Immunic's average media sentiment score of 0.74 beat Ovid Therapeutics' score of 0.29 indicating that Ovid Therapeutics is being referred to more favorably in the news media.
51.8% of Immunic shares are held by institutional investors. Comparatively, 72.2% of Ovid Therapeutics shares are held by institutional investors. 3.0% of Immunic shares are held by insiders. Comparatively, 13.3% of Ovid Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Immunic presently has a consensus price target of $8.50, suggesting a potential upside of 585.48%. Ovid Therapeutics has a consensus price target of $8.08, suggesting a potential upside of 164.16%. Given Ovid Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Immunic is more favorable than Ovid Therapeutics.
Summary
Ovid Therapeutics beats Immunic on 12 of the 17 factors compared between the two stocks.
Get Ovid Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for OVID and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding OVID and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Ovid Therapeutics Competitors List
Related Companies and Tools
